9/10/2008

The National Institute of Allergy and Infectious Diseases awarded XOMA a $65 million contract to develop a treatment for botulism, a potentially lethal disease caused by a neurotoxin from the bacterium Clostridium botulinum. XOMA intends to begin trials next year for its first antibody product against the disease.

Related Summaries